Europe's medicines regulator has added the extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a possible side-effect of AstraZeneca's COVID-19 vaccine.
The European Medicines Agency said there was a causal relationship between GBS and the AstraZeneca shot, after 833 cases of GBS were reported out of 592 million doses of the vaccine given worldwide by July 31.
The EMA categorised the side-effect as "very rare", which is the lowest frequency of side-effect category it has, and has emphasised that the benefits of the shot outweigh the risks.
The U.S. Food and Drug Administration has added a warning over Guillain-Barré syndrome as a possible side-effect of Johnson & Johnson's shot.
Both vaccines use viral vector technology, and have also been associated with rare blood clots.
comments powered by Disqus
All feeds
